Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 46 results
Filters: First Letter Of Title is S  [Clear All Filters]
Found 46 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

S

Evans SR, Clifford DB, Kitch DW, et al. "Simplification of the research diagnosis of HIV-associated sensory neuropathy." HIV Clin Trials. 2008;9(6):434-9.
Robbins GK, Testa MA, Su M, et al. "Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384." HIV Clin Trials. 2013;14(5):235-53.
Li JZ, Etemad B, Ahmed H, et al. "The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption." AIDS. 2016;30(3):343-53.
Naggie S, Marks KM, Hughes M, et al. "Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C." Clin. Infect. Dis.. 2017;64(8):1035-1042.
Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AMarie, Aberg JA. "Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332." Inflammation. 2016;39(4):1354-62.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Sieg SF, Bazdar DA, Lederman MM. "S-phase entry leads to cell death in circulating T cells from HIV-infected persons." J. Leukoc. Biol.. 2008;83(6):1382-7.
Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. "Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort." Antivir. Ther. (Lond.). 2009;14(6):853-8.
Liu D, Yu J, Chen H, Reichman R, Wu H, Jin X. "Statistical determination of threshold for cellular division in the CFSE-labeling assay." J. Immunol. Methods. 2006;312(1-2):126-36.
Pei L, Hughes MD. "A statistical framework for quantile equivalence clinical trials with application to pharmacokinetic studies that bridge from HIV-infected adults to children." Biometrics. 2008;64(4):1117-25.
Schouten JT, Krambrink A, Ribaudo HJ, et al. "Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095." Clin. Infect. Dis.. 2010;50(5):787-91.
Kalayjian RC, Franceschini N, Gupta SK, et al. "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease." AIDS. 2008;22(4):481-7.
Yamamoto T, Price DA, Casazza JP, et al. "Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection." Blood. 2011;117(18):4805-15.
Godfrey C, Tauscher G, Hunsberger S, et al. "A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries." BMC Infect. Dis.. 2016;16:269.
Sherman KE, Andersen JW, Butt AA, et al. "Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)." J. Acquir. Immune Defic. Syndr.. 2010;55(5):597-605.
Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.

Pages